mRNA Technology: Where Science Meets the Next Wave of Life Science Investment
Join The Life Science Cluster, Farvatn and Framdrift for an evening of insights, discussion, and networking, exploring the next wave of mRNA innovation—from new therapeutic applications and AI-driven drug discovery to emerging market opportunities.
The global mRNA vaccine and therapeutics market is projected to reach USD 68.1 billion by 2030, with annual growth estimates ranging from 8.8% to 13.2%. Once associated primarily with infectious disease vaccines, mRNA technology is expanding into oncology, autoimmune disease, and pandemic preparedness. For investors, understanding this shift early can help uncover opportunities as the field evolves.
This investor-focused gathering will help you navigate the complexity: where the science is heading, how large the opportunity could be, and what it takes to evaluate investments with confidence.
Speakers from science, technology, and investment will explore the advances driving this transformation, the AI-powered platforms accelerating drug discovery, and the market dynamics shaping capital flows. Whether you have a scientific background or are new to the field, the session will give you a clearer understanding of the investment landscape.
The event is followed by dinner, offering an opportunity to continue the conversation and connect with fellow investors and speakers.
Seats are limited to encourage focused discussion and give participants direct access to the speakers.
Agenda
Moderator: To be announced
16.00-16.10: Welcome, Delphine Costa (TLSC)
16.10-16.32: Investing in Life Sciences What it takes to back the next breakthrough, Lars Mørland Knudsen (P53) & Georgina Askeland (Hadean Ventures)
16.32-16.44: Founder(s) on Stage Company pitches: companies pitch their path to market, Peter W. Eide & Jarle Bruun (Oncosyne)
16.44-16.54: Q&A with the Founders. Open to questions from the audience and investors
16.54-17.16: Inside Revolution Medicines, Benedicte Bakke (DNB)
17.16-17.38: Next Generation of Vaccines How vaccine innovation is evolving beyond COVID, Arun Kumar (CEPI)
17.38-17.55: Fireside Chat Reflections on mRNA vaccine treatment, Kristin Mohn (Haukeland University Hospital) & Kristin Odfjell (Farvatn)
17.55-18.00: Closing Thoughts, Shokouh Makvandi-Nejad (TLSC)